{"altmetric_id":2431810,"counts":{"readers":{"mendeley":188,"citeulike":1,"connotea":0},"policy":{"unique_users_count":1,"unique_users":["nice"],"posts_count":6},"total":{"posts_count":6}},"citation":{"abstract":"The aim of this study was to develop a simulation model for type 2 diabetes that can be used to estimate the likely occurrence of major diabetes-related complications over a lifetime, in order to calculate health economic outcomes such as quality-adjusted life expectancy.","abstract_source":"pubmed","altmetric_jid":"4f6fa6143cf058f610007106","authors":["P. M. Clarke","A. M. Gray","A. Briggs","A. J. Farmer","P. Fenn","R. J. Stevens","D. R. Matthews","I. M. Stratton","R. R. Holman","on behalf of the UK Prospective Diabetes Study (UKPDS) Group","Clarke PM","Gray AM","Briggs A","Farmer AJ","Fenn P","Stevens RJ","Matthews DR","Stratton IM","Holman RR"],"doi":"10.1007\/s00125-004-1527-z","endpage":"1759","first_seen_on":"2014-06-13T00:32:52+00:00","issns":["1432-0428","0012-186X"],"issue":"10","journal":"Diabetologia","last_mentioned_on":1450828800,"links":["http:\/\/dx.doi.org\/10.1007\/s00125-004-1527-z"],"pmid":"15517152","pubdate":"2004-11-03T00:00:00+00:00","publisher_subjects":[{"name":"Human Physiology","scheme":"springer"},{"name":"Internal Medicine","scheme":"springer"},{"name":"Medicine & Public Health","scheme":"springer"},{"name":"Metabolic Diseases","scheme":"springer"},{"name":"Clinical Sciences","scheme":"era"},{"name":"Paediatrics And Reproductive Medicine","scheme":"era"},{"name":"Public Health And Health Services","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"startpage":"1747","subjects":["endocrinology"],"title":"A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68)","type":"article","uri":"http:\/\/link.springer.com\/10.1007\/s00125-004-1527-z","volume":"47","mendeley_url":"http:\/\/www.mendeley.com\/research\/model-estimate-lifetime-health-outcomes-patients-type-2-diabetes-united-kingdom-prospective-diabetes"},"altmetric_score":{"score":3,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":3},"context_for_score":{"all":{"total_number_of_other_articles":8163518,"mean":6.8970466082141,"rank":2060829,"this_scored_higher_than_pct":60,"this_scored_higher_than":4971542,"rank_type":"exact","sample_size":8163518,"percentile":60},"similar_age_3m":{"total_number_of_other_articles":178739,"mean":7.4046026698298,"rank":47218,"this_scored_higher_than_pct":71,"this_scored_higher_than":126952,"rank_type":"exact","sample_size":178739,"percentile":71},"this_journal":{"total_number_of_other_articles":2247,"mean":15.26211398041,"rank":886,"this_scored_higher_than_pct":42,"this_scored_higher_than":961,"rank_type":"exact","sample_size":2247,"percentile":42},"similar_age_this_journal_3m":{"total_number_of_other_articles":56,"mean":18.549127272727,"rank":17,"this_scored_higher_than_pct":60,"this_scored_higher_than":34,"rank_type":"exact","sample_size":56,"percentile":60}}},"demographics":{"users":{"mendeley":{"by_status":{"Unspecified":2,"Professor > Associate Professor":13,"Librarian":1,"Researcher":50,"Student  > Doctoral Student":1,"Student  > Ph. D. Student":33,"Student  > Postgraduate":9,"Student  > Master":37,"Other":17,"Student  > Bachelor":4,"Lecturer":6,"Lecturer > Senior Lecturer":2,"Professor":13},"by_discipline":{"Medicine and Dentistry":102,"Social Sciences":5,"Decision Sciences":1,"Psychology":5,"Mathematics":7,"Unspecified":12,"Pharmacology, Toxicology and Pharmaceutical Science":8,"Engineering":2,"Neuroscience":1,"Economics, Econometrics and Finance":18,"Agricultural and Biological Sciences":13,"Computer Science":5,"Business, Management and Accounting":6,"Nursing and Health Professions":2,"Biochemistry, Genetics and Molecular Biology":1}}},"geo":{"mendeley":{"EC":1,"US":5,"GB":5,"PT":1,"ES":1,"IN":1,"NZ":2,"CA":3,"NL":1,"BE":1,"IE":1,"DK":1,"BR":2}}},"posts":{"policy":[{"title":"Canagliflozin in combination therapy for treating type\u00a02 diabetes: Diabetes (type 2) - canagliflozin: evaluation report","url":"https:\/\/www.nice.org.uk\/guidance\/TA315\/documents\/diabetes-type-2-canagliflozin-evaluation-report4","license":"public","citation_ids":[1522703,9708663,2431917,1345763,1478530,15779855,15779861,6955397,846304,15779864,1669837,2417969,1407297,703916,651550,20591123,735571,14840223,14781824,1560032,15779875,15779878,199380,15361150,15361151,185599,15779885,15779891,179823,15779896,15779899,8254612,1582472,15779905,6719714,2431846,15779916,964031,11851759,2431810,9708660,15779918,14426434,9647628,1145378,2037262,2588160,15779934,4323582,1727635,2412926,690979,15779940,11846303,1591812,2873136,682946,3252490,1279321,15779958,15779963,1421805,701469,704465,15779981,715616,766581,1284498,4188817,698998,1243381,15780000,3179284,1668050,3453415,1329496,15780013,1284734,5428708,386549,7401056,200892,15754180],"posted_on":"2014-02-24T00:00:00+00:00","source":{"name":"National Institute for Health and Care Excellence","description":"The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.","geo":{"country":"GB"}},"page_url":"https:\/\/www.nice.org.uk\/guidance\/ta315\/evidence","collections":[],"author":{"image":"https:\/\/s3.amazonaws.com\/cache.altmetric.com\/policy\/thumbnails\/thumbnail-e2d2219265ade126b453e4f77092a4f524e8844df17b4d3b9c6650df1e89472a.jpg"}},{"title":"Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia : Committee papers","url":"https:\/\/www.nice.org.uk\/guidance\/TA385\/documents\/committee-papers","license":"public","citation_ids":[4947578,15783446,21723365,15783450,2156122,15783580,15783461,3881637,21723372,15774273,5373557,15783469,15783473,15783477,1628308,21723378,1872293,15374538,2114111,15777662,15780686,1831600,9647628,1094946,1816044,1757457,2835859,15777688,15783498,15777681,2417930,2415218,6235740,2515943,6235475,5978789,2704046,15777668,1731577,1305306,15783519,1849738,15783525,15774301,15777711,15777719,125314,15783532,15783536,15777704,2431901,2431810,4671635,2254776,5364040,15783546,5364068,15772049,2132822,1328074,905092,15783552,174025,15783557,15783559,15783565,15783569,15783570,15783577,15783582,15783584,15783592,15783600,15783599,15783603,609065,15783610,15783613,2840255,4214488,15783609,15783625,2840295,3823966,15783633,581290,15783638,2403307,15783649,5705353,748480,1445080,1959899,4303510,456096,3205791,2840260,1639951,15783669,2557865,2151863,1531922,211278,15783683,3193881,14581119,3209099,124630,187269,6122431,101315,235854,2412941],"posted_on":"2015-10-21T00:00:00+00:00","source":{"name":"National Institute for Health and Care Excellence","description":"The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.","geo":{"country":"GB"}},"page_url":"https:\/\/www.nice.org.uk\/guidance\/ta385\/evidence","collections":[],"author":{"image":"https:\/\/s3.amazonaws.com\/cache.altmetric.com\/policy\/thumbnails\/thumbnail-6fc9914628e03b7747c36f62ddfc17a998a331259b9f226b2b604429f557addf.jpg"}},{"title":"Type 2 diabetes in adults: management: Appendix F: Full health economics report","url":"https:\/\/www.nice.org.uk\/guidance\/ng28\/evidence\/appendix-f-full-health-economics-report-2185320355","license":"public","citation_ids":[15784717,15784721,15609748,2680624,9505061,5983282,15778301,2431836,15784741,1669837,6337128,15784751,15784760,15784763,2588160,14621397,15784803,15784808,15784810,715616,5979306,3353896,1582472,15776036,2412505,2426752,15784812,1008351,4041139,15397336,622737,9647628,14426434,2431810,15784822,15781547,4268058,15784827,2473666,9708663,9708660,1997462,2037262,15784834,15784836,15784839,15784840,861243,1604713],"posted_on":"2015-12-02T00:00:00+00:00","source":{"name":"National Institute for Health and Care Excellence","description":"The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.","geo":{"country":"GB"}},"page_url":"https:\/\/www.nice.org.uk\/guidance\/ng28\/evidence","collections":[],"author":{"image":"https:\/\/s3.amazonaws.com\/cache.altmetric.com\/policy\/thumbnails\/thumbnail-0baec4ba134f8a807865a4c2e6c0ac1a62bde1f5825a97baad051b4253a2edad.jpg"}},{"title":"Type 2 diabetes in adults: management: Appendix I: NICE guideline CG87 deleted appendix","url":"https:\/\/www.nice.org.uk\/guidance\/ng28\/evidence\/appendix-i-nice-guideline-cg87-deleted-appendix-78671532564","license":"public","citation_ids":[15785280,15785301,604440,248120,5456786,6586438,673474,15785332,4041139,6235453,2431810,15778291,15785351,15785356,8246469,9505048,9505056,15785368,9505047,15779918,15785374,15785379,15781547,15778301,15785383,14426434,2431836,8245098,15785390,15785401,9708660,15785405,15785408,15785413,15785417,2431803,15778331,15785421,528981,15785425,15785431,15785435,15785441,138571,15785443,15785447,173535,4643537,1444981,15785458,536003,1444980,1205811,173886,134422,173885,173526,9505044,1693285,1533754,15785471,1690884,15778324,2515560,3878759,15785476,15785484,2431845,15785493,15785498,15785503,15785507,15785511,15785518,2431890,15785529,15785532,15785538,15785542,15785545,15785552,15785573,15785578,15785581,15785587,1652802,15785592,15785597,15785600,15785605,2420857,15785609,15785613,15785621,15785625,15785629,15785636,15785641,15785648,15785663,15785664,15785666,15785672,15785677,15785685,15785691,15785692,5727799,15785698,3020450,15785704,15785708,15785712,2905376,15785723,1565594,15785726,15785728,15785729,4188954,3196684,2431899,15785731,15785733,15785736,15778278,15778345,15785741,3353896,15778365,15778372,9872335,15785760,15785767,15785770,15785773,15785776,3431355,15785779,3792358,2708642,15785783,7625859,185599,15785789,15785793,2431814,15785795,15785798,15785802,15785805,15785810,974903,15779981,15785822,15785824,15785827,3168131,15785831,15785838],"posted_on":"2015-12-02T00:00:00+00:00","source":{"name":"National Institute for Health and Care Excellence","description":"The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.","geo":{"country":"GB"}},"page_url":"https:\/\/www.nice.org.uk\/guidance\/ng28\/evidence","collections":[],"author":{"image":"https:\/\/s3.amazonaws.com\/cache.altmetric.com\/policy\/thumbnails\/thumbnail-d7110a427b2a2b88ea98de353816573f5dd89cd2255fd724329e26fbc6e65eda.jpg"}},{"title":"Empagliflozin in combination therapy for treating type\u00a02\u00a0diabetes: Diabetes (type 2) - empagliflozin [ID641]: evaluation report","url":"https:\/\/www.nice.org.uk\/guidance\/ta336\/documents\/diabetes-type-2-empagliflozin-id641-evaluation-report2","license":"public","citation_ids":[9647628,2431810,19492405,14426434,1529860],"posted_on":"2014-08-26T15:49:24+00:00","source":{"name":"National Institute for Health and Care Excellence","description":"The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.","geo":{"country":"GB"}},"page_url":"https:\/\/www.nice.org.uk\/guidance\/ta336\/evidence","collections":[],"author":{"image":"https:\/\/s3.amazonaws.com\/cache.altmetric.com\/policy\/thumbnails\/thumbnail-d7d177396e77333ee71cee11b31a0937a62592a0ba8fba7744c02406b0f3a39d.jpg"}},{"title":"Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes: Committee papers","url":"https:\/\/www.nice.org.uk\/guidance\/TA390\/documents\/committee-papers","license":"public","citation_ids":[4111497,4225581,4528152,9708660,15779918,1628308,20551637,2966355,1800064,2169944,2588160,20551655,20551663,20551676,20551687,1865786,15780000,20551705,15785629,15785625,20551717,20551724,545277,1398810,15785641,20551735,15785672,2029259,15785685,20551751,452871,4143551,2008582,16026039,16025612,20551800,798411,15784810,2010983,2431821,20551820,20551830,5727799,20551839,2212351,20551853,210678,20551861,15776049,18386218,20551882,20550804,15785704,20551889,786683,20551897,20551906,944452,855073,2905376,20551929,1132751,1258288,1368022,3009272,704465,4322169,2431842,15779878,423807,663646,1268918,1292983,715616,3262478,1738921,20551959,1293093,1096663,1478530,15776036,2416235,9647628,3191359,15751062,1008351,2256662,14426434,2547252,1368033,200892,2431810,2321920,1582472,2221469,15785609,1529860,1727635,20535748,20552000,16025992,20552014,20552026,617557,20552044,1018707,469015,1172865,20552061,1826454,2934315,668734,3753038,1740965,444052,20552094,2874405,741128,2763254,20552119,20552122,15776038,15779896,15033797,1297073,20552139,255012,20552150,2473666,2057775,7404750,1284498,2224945,2070125,20552159,15785545,651550,20552171,20552176,185599,1724135,16161757,173676,832124,3453415,15776040,786738,1445007,4690573,4687329,20552265],"posted_on":"2015-12-23T00:00:00+00:00","source":{"name":"National Institute for Health and Care Excellence","description":"The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.","geo":{"country":"GB"}},"page_url":"https:\/\/www.nice.org.uk\/guidance\/ta390\/evidence","collections":[],"author":{"image":"https:\/\/s3.amazonaws.com\/cache.altmetric.com\/policy\/thumbnails\/thumbnail-975790d5475c5af3397c9524f90bc09a140004595c480117c01f2935cb88d99e.jpg"}}]}}